Table 2.

Reasons for the determinations of package selection and treatment appropriateness

	Both		Public	Private
	Count	Percent	Count	Count
Cannot assess appropriateness of package selection or treatment (n = 5)
No documentation of metastasis or gap between Palliative care chemotherapy date and breast cancer surgery	3	60%	0	3
Discrepancy in regimen listed on consent form and the clinical notes	2	40%	2	0
Inappropriate package selection (n = 30)
Inappropriate package selection and inappropriate treatment (n = 3)
Inappropriate package selection (treatment appropriateness could not be not assessed) (n = 27)
No documentation of metastatic disease and Palliative care chemotherapy started within 6 months of breast cancer surgery	21	70%	7	14
Biopsy showed diagnosis of cancer other than breast cancer	2	7%	1	1
Drugs that are not chemotherapy used	4	13%	4	0
Appropriate package selection (n = 15)
Likely to be appropriate package selection (treatment appropriateness could not be not assessed) (n = 6)
Documented breast cancer + documented metastasis or more than 6 months gap between chemotherapy date and surgery + 2nd line Palliative care chemotherapy given but no documentation of 1st line therapy	6	40%	5	1
Likely to be appropriate package selection and treatment (n = 9)
Documented breast cancer + documented metastasis or more than 6 months gap between chemotherapy date and surgery + 1st line palliative care chemotherapy	7	47%	4	3
Documented breast cancer + documented metastasis or more than 6 months gap between chemotherapy date and surgery + 2nd line palliative care chemotherapy with documented evidence of previous first line treatment	2	13%	2	0